Clinical trials: Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
This is a study for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received treatment with at least a BTK inhibitor.
- Trial name
- BRUIN CLL-321 (NCT04666038)
- Testing
- Pirtobrutinib, Idelalisib, Bendamustine
- Where
- 232 sites in United States, Australia and 22 more
- Volunteers
- 238 people
- Sponsor
- Loxo Oncology, Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07
A Phase 3 (extension) clinical trial to examine the efficacy of IPI-145 (duvelisib) monotherapy or ofatumumab monotherapy in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who experienced…
- Trial name
- NCT02049515
- Testing
- IPI-145, Ofatumumab
- Where
- 69 sites in United States, Australia and 9 more
- Volunteers
- 99 people
- Sponsor
- SecuraBio
Leukemia
506U78 in Treating Patients With Chronic Lymphocytic Leukemia That Has Not Responded to Fludarabine or Alkylating Agents
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of 506U78 in treating patients with chronic lymphocytic…
- Trial name
- NCT00003635
- Testing
- nelarabine
- Where
- 22 sites in United States
- Sponsor
- GlaxoSmithKline
Cancer - Chronic Lymphocytic Leukemia
Study Venetoclax Effectiveness and Real-Life Treatment Management in Participants With Chronic Lymphocytic Leukemia
This study will evaluate real-life effectiveness and use in participants starting venetoclax treatment for Chronic Lymphocytic Leukemia (CLL).
- Trial name
- VERONE (NCT03415035)
- Where
- 60 sites in France
- Volunteers
- 269 people
- Sponsor
- AbbVie
Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia in Remission
Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes
This randomized phase II trial studies how well donor umbilical cord blood transplant with or without ex-vivo expanded cord blood progenitor cells works in treating patients with acute myeloid leukemia, acute lymphoblastic…
- Conditions
- Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Chronic Myelogenous Leukemia
- Trial name
- NCT01690520
- Testing
- Cyclophosphamide, Cyclosporine, Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion
- Where
- 8 sites in United States
- Volunteers
- 163 people
- Sponsor
- Nohla Therapeutics, Inc.
Leukemia, Lymphoma
Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
The purpose of this study is to evaluate the efficacy of BGB-11417 in participants with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
- Conditions
- Leukemia, Lymphoma, Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma
- Trial name
- NCT05479994
- Testing
- BGB-11417
- Where
- 50 sites in China
- Volunteers
- 100 people
- Sponsor
- BeiGene
Chronic Myelogenous Leukemia, Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Rollover Study of BMS-354825 in Patients With CML and Ph+ALL
To assess the safety of dasatinib (BMS-354825) in subjects with Imatinib resistant or intolerant chronic myelogenous leukemia (CML) and Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) who are resistant…
- Trial name
- NCT01030718
- Testing
- dasatinib
- Volunteers
- 54 people
- Sponsor
- Bristol-Myers Squibb
Chronic Lymphocytic Leukemia
A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy
This was an open-label, non-randomized, multicenter, Phase 2 study evaluating the efficacy and safety of ABT-199 in 127 participants with relapsed or refractory chronic lymphocytic leukemia (CLL) after B-cell receptor signaling…
- Trial name
- NCT02141282
- Testing
- Venetoclax
- Where
- 15 sites in United States
- Volunteers
- 127 people
- Sponsor
- AbbVie
Myelogenous Leukemia, Acute, Leukemia, Lymphocytic, Acute
Study of SCH 900776 (MK-8776) With and Without Cytarabine in Participants With Acute Leukemias (P05247)
This study of SCH 900776 (MK-8776) will evaluate its safety and tolerability when given in combination with cytarabine to participants with acute leukemias.
- Conditions
- Myelogenous Leukemia, Acute, Leukemia, Lymphocytic, Acute, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Myelogenous Leukemia, Chronic, Aggressive Phase
- Trial name
- NCT00907517
- Testing
- MK-8776, Cytarabine
- Volunteers
- 24 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Lymphocytic Leukemia
Safety and Efficacy of the Combination of Tirabrutinib and Entospletinib With and Without Obinutuzumab in Adults With Chronic Lymphocytic Leukemia (CLL)
The primary objective of this study is to determine the preliminary efficacy of the combination of tirabrutinib (formerly GS-4059) and entospletinib with obinutuzumab in adults with relapsed or refractory chronic lymphocytic…
- Trial name
- NCT02983617
- Testing
- Tirabrutinib, Entospletinib, Obinutuzumab
- Where
- 15 sites in Germany
- Volunteers
- 36 people
- Sponsor
- Gilead Sciences
Relapsed or Refractory Non-Hodgkin's Lymphoma, Relapsed or Refractory Multiple Myeloma
Study of BEBT-908 in Subjects With Advanced Hematological Tumors
The purpose of this study was to evaluate the safety and tolerance of BEBT-908 for injection in the treatment of recurrent refractory malignant lymphoma, multiple myeloma and chronic lymphoblastic leukemia, and to obtain the…
- Trial name
- NCT06082596
- Testing
- BEBT-908 for injection
- Where
- China
- Volunteers
- 32 people
- Sponsor
- BeBetter Med Inc
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
VEGF Trap in Treating Patients With Solid Tumors or Non-Hodgkin's Lymphoma
RATIONALE: VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the cancer. PURPOSE: Phase I trial to study the effectiveness of VEGF Trap in treating patients who have relapsed or…
- Trial name
- NCT00045266
- Testing
- ziv-aflibercept
- Where
- United States
- Sponsor
- Regeneron Pharmaceuticals
Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma
Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
This was a single-arm, open-label, multi-center Phase 2 study in participants with histologically documented CLL/SLL who have relapsed after or refractory to ≥ 1 prior treatment regimen(s).
- Trial name
- NCT03206918
- Testing
- Zanubrutinib
- Where
- 11 sites in China
- Volunteers
- 91 people
- Sponsor
- BeiGene
B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19-positive hematologic malignancies.
- Conditions
- B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Trial name
- NCT06533579
- Testing
- Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101
- Where
- 11 sites in United States
- Volunteers
- 32 people
- Sponsor
- Vironexis Biotherapeutics Inc.
Leukemia, Lymphocytic, Chronic
Alvocidib in Patients With Previously Treated Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Arising From Chronic Lymphocytic Leukemia (CLL)
Multicenter, open-label, study of alvocidib in previously treated chronic lymphocytic leukemia patients. Primary objective is to determine overall response rate.
- Trial name
- NCT00464633
- Testing
- alvocidib
- Where
- 34 sites in United States, Australia and 7 more
- Volunteers
- 165 people
- Sponsor
- Sanofi
Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
The purpose of this extension study is to provide venetoclax and obtain long-term safety data for subjects who continue to tolerate and derive benefit from receiving venetoclax in ongoing studies.
- Conditions
- Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Non-Hodgkin's Lymphoma
- Trial name
- NCT03844048
- Testing
- Venetoclax
- Where
- 56 sites in United States, Australia and 21 more
- Volunteers
- 165 people
- Sponsor
- AbbVie
Lymphoma, B-Cell, Chronic Lymphocytic Leukemia
FT819 in Subjects With B-cell Malignancies
This is a Phase I dose-finding study of FT819 as monotherapy and in combination with IL-2 in subjects with relapsed/refractory B-cell Lymphoma, Chronic Lymphocytic Leukemia and Precursor B-cell Acute Lymphoblastic Leukemia.
- Conditions
- Lymphoma, B-Cell, Chronic Lymphocytic Leukemia, Precursor B-Cell Acute Lymphoblastic Leukemia
- Trial name
- NCT04629729
- Testing
- FT819, Cyclophosphamide, Fludarabine
- Where
- 18 sites in United States
- Volunteers
- 54 people
- Sponsor
- Fate Therapeutics
Chronic Myeloid Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-positive
Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
The purpose of this clinical research study is to learn if BMS-354825 will have activity as defined by hematologic responses in subjects with lymphoid blast phase chronic myeloid leukemia (CML) and Philadelphia chromosome…
- Trial name
- NCT00101595
- Testing
- Dasatinib
- Where
- 60 sites in United States, Argentina and 18 more
- Volunteers
- 96 people
- Sponsor
- Bristol-Myers Squibb
Chronic Lymphocytic Leukemia, Hypogammaglobulinemia
Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)
Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients with Chronic Lymphocytic Leukemia
- Trial name
- NCT04502030
- Testing
- Panzyga
- Where
- 84 sites in United States, Czechia and 10 more
- Volunteers
- 247 people
- Sponsor
- Octapharma
Lymphocytic Leukemia, Chronic, Diffuse Large B-Cell Lymphoma
A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.
This open-label, Phase I study will evaluate the safety, tolerability, and pharmacokinetics of increasing doses of GDC-0853 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma or chronic lymphocytic leukemia.
- Trial name
- NCT01991184
- Testing
- GDC-0853
- Where
- 10 sites in United States, Australia
- Volunteers
- 24 people
- Sponsor
- Genentech, Inc.